The market is suffering from a 'three-body problem,' says BTIG's Jonathan Krinsky
Jonathan Krinsky, chief market technician at BTIG, joins CNBC's 'The Exchange to discuss his outlook on stocks for 2025, what ...
GeneDx management to meet with BTIG
BTIG Life Sciences and Diagnostic Tools Analyst Massaro holds group dinner meeting with CEO Stueland and CFO Feeley on January 13 at 10:30 am.
24/7 Wall St. on MSN3d
Large-Cap Value Stocks Could Rule in 2025: 4 High-Yield Dividend Winners
Here are four large-cap value stocks that growth and income investors may want to consider now. History suggests they will ...
Energy stocks take ‘early lead’ in 2025 as natural gas shines
“In 2025, the energy sector will be less about barrels of oil and more about...billions of cubic feet of natural gas demand ...
Stock rally faces resistance: BTIG's Krinsky
The S&P 500's rally of 1.8% over just the last two sessions is nice, "but not a game changer yet," according to BTIG's technical guru, Jonathan Krinsky. The chart he provides, below, shows the stock ...
Here are some of BTIG's top picks for the first half of 2025
BTIG's Krinsky noted that while equity markets in the first half of 2024 were fueled mostly by the surge in mega-cap names ...
Nasdaq24d
SentinelOne named ‘Top Pick’ for Security in 2025 at BTIG
BTIG analyst Gray Powell keeps a Buy rating and $30 price target on SentinelOne (S) but names the stock the firm’s Top Pick in Security & Infrastructure Software for 2025. The stock is ...
Apple investors may want to brace for a sell-off
Apple (AAPL) shares are up about 8% over the past month. But BTIG chief market technician Jonathan Krinsky is warning ...
Investing11d
BTIG sees a risk for 'a bigger January decline' in S&P 500
According to a BTIG strategist, the rally in the index was rejected from the previous support trendline and even though there are still four days left for the Santa Claus rally to deliver gains, there ...
Nasdaq1mon
BTIG Initiates Coverage of Avalo Therapeutics (AVTX) with Buy Recommendation
As of December 3, 2024, the average one-year price target for Avalo Therapeutics is $35.70/share. The forecasts range from a low of $35.35 to a high of $36.75. The average price target represents ...
MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG
BTIG raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $81 from $71 and keeps a Buy rating on the shares. The firm ...